# Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

> **NCT02307500** · PHASE2 · COMPLETED · sponsor: **Istituto Clinico Humanitas** · enrollment: 82 (actual)

## Conditions studied

- Pancreas Cancer
- Ovarian Cancer
- Melanoma
- Sarcoma
- Thymoma Type B3
- Thymoma Type B2
- Thymic Carcinoma

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02307500
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-12
- **Final completion:** 2020-08
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307500, "Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02307500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*